Image pharmaphorum Editor Views & Analysis Delivering innovative therapies with close industry-NHS part... It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Oncology Sponsored Cost & Management of Oncology Combination Regimens Overview Views & Analysis Translating microbiome research into treatments The human microbiome is a powerful and dynamic ecosystem of microbes that live on and within our bodies. Views & Analysis Building our own community for an ultra-rare disease Bo Bigelow shares the story of his daughter Tess, who has an ultra-rare genetic disorder with only 51 known cases in the world. Load more results
Views & Analysis Delivering innovative therapies with close industry-NHS part... It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE)
Views & Analysis Translating microbiome research into treatments The human microbiome is a powerful and dynamic ecosystem of microbes that live on and within our bodies.
Views & Analysis Building our own community for an ultra-rare disease Bo Bigelow shares the story of his daughter Tess, who has an ultra-rare genetic disorder with only 51 known cases in the world.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
